Treatment with the anti–IL-6 drug, tocilizumab, can prevent CRS in mouse models but not abolish neurotoxicity (41, 50), whereas the natural IL-1 receptor antagonist (IL-1RA; human IL-1RA also known as anakinra) can prevent severe CRS and fatal neurotoxicity. This evidence concerns the gene IL6 and congenital rubella syndrome.